AcouSort AB AI Stock Analysis
Want to see SE:ACOU full AI Analyst Report?
AcouSort AB (ACOU) AI Stock Analysis
AcouSort AB
(Nasdaq OMX AB:ACOU)
The overall score of 40 reflects AcouSort's combination of weak fundamental operations and poor market momentum. The most significant risks are the company's deep unprofitability, negative gross margins, and a heavy bearish technical trend across all moving averages. While a debt-free balance sheet mitigates immediate insolvency risks, the continued cash burn and highly negative valuation metrics constrain the stock's near-term outlook.
AcouSort AB (ACOU) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 58.62M
- Dividend Yield
- ―
- Average Volume (3M)
- 37.34K
- Price to Earnings (P/E)
- -5.3
- Beta (1Y)
- 0.01
- Revenue Growth
- 43.22%
- EPS Growth
- 36.11%
- Country
- Sweden
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
AcouSort AB Business Overview & Revenue Model
Company Description
AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular v...
How the Company Makes Money
AcouSort AB makes money primarily by commercializing its acoustofluidic separation technology to customers who need to integrate cell/particle separation and washing into their instruments or manufacturing workflows. Key revenue streams include: (1)...
AcouSort AB Financial Statement Overview
Summary
AcouSort exhibits severe profitability challenges, including negative gross margins and consistent net losses. While ongoing equity burn and cash outflows present structural risks, the company's pristine debt-free balance sheet provides a critical buffer against immediate insolvency.
Income Statement
25NegativeBalance Sheet
65PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.97M | 6.85M | 4.74M | 10.55M | 4.96M | 3.01M |
| Gross Profit | -7.90M | -14.50M | 4.77M | 8.39M | 2.91M | 548.00K |
| EBITDA | -12.17M | -14.33M | -15.89M | -16.70M | -12.86M | -11.46M |
| Net Income | -11.22M | -12.15M | -15.08M | -17.09M | -13.21M | -12.38M |
Balance Sheet | ||||||
| Total Assets | 21.47M | 17.89M | 12.32M | 34.51M | 42.66M | 36.56M |
| Cash, Cash Equivalents and Short-Term Investments | 9.48M | 6.29M | 3.57M | 23.99M | 33.97M | 31.52M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 11.67M | 1.59M | 3.86M | 10.38M | 22.54M | 3.54M |
| Stockholders Equity | 9.81M | 16.30M | 8.46M | 24.14M | 20.11M | 33.02M |
Cash Flow | ||||||
| Free Cash Flow | -6.91M | -17.27M | -19.84M | -31.77M | 2.95M | -12.23M |
| Operating Cash Flow | -6.58M | -16.78M | -18.81M | -31.56M | 3.96M | -10.92M |
| Investing Cash Flow | -1.39M | -488.00K | -1.02M | -1.16M | -1.01M | -1.31M |
| Financing Cash Flow | -118.00K | 18.98M | -157.00K | 22.08M | 0 | 35.63M |
AcouSort AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACOU, the sentiment is Negative. The current price of 2.70 is below the 20-day moving average (MA) of 3.06, below the 50-day MA of 3.02, and below the 200-day MA of 3.33, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 43.00 is Neutral, neither overbought nor oversold. The STOCH value of 38.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACOU.
AcouSort AB Peers Comparison
Overall Rating
SE:CEVI83Outperform
SE:FLUI65Neutral
SE:IMMNOV46Neutral
SE:BICO40Underperform
SE:ACOU40Underperform
SE:QLINEA31Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | SEK 4.85B | 35.21 | 15.23% | 1.35% | 1.95% | -8.91% | |
| 65Neutral | SEK 32.83M | 6.37 | 34.47% | ― | 630.57% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | SEK 85.83M | -0.28 | -215.44% | ― | 148.66% | 66.30% | |
| 40Underperform | SEK 1.10B | -5.05 | -28.59% | ― | -5.27% | 34.38% | |
| 40Underperform | SEK 58.62M | -5.25 | -76.74% | ― | 43.22% | 36.11% | |
| 31Underperform | SEK 235.91M | -1.44 | -48.10% | ― | 33.26% | 90.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ACOU | AcouSort AB | 2.70 | 0.03 | 1.12% | |
| SE:BICO | BICO Group AB Class B | 15.92 | -2.12 | -11.75% | |
| SE:CEVI | CellaVision AB | 204.00 | 50.42 | 32.83% | |
| SE:IMMNOV | Immunovia AB | 0.05 | -0.12 | -70.93% | |
| SE:QLINEA | Q-linea AB | 11.35 | -14.07 | -55.35% | |
| SE:FLUI | Fluicell AB | 21.70 | 10.30 | 90.35% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
